Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adicet Bio, Inc. - Common Stock (NQ:ACET)

6.250 -0.220 (-3.40%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adicet Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Adicet Bio’s Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months ↗
Adicet Bio (NASDAQ:ACET) reported positive clinical data for prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus, or SLE, including... 
Via MarketBeat
News headline image
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
From Adicet Bio, Inc.
Via Business Wire
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
Via Chartmill
News headline image
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗
One of J&J's investments stands head-and-shoulders above the rest. 
Via The Motley Fool
News headline image
Adicet Bio Announces FDA Clearance of IND Application for ADI-212
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy ↗
Adicet Bio (NASDAQ:ACET) expects to report clinical data this quarter for its lead autoimmune program, ADI-001, also known as prula-cel, including results in lupus nephritis (LN) and systemic lupus... 
Via MarketBeat
News headline image
Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference
From Adicet Bio, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million. Bio-Techne (NASDAQ:TECH)... 
Via Benzinga
News headline image
Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference ↗
Adicet Bio (NASDAQ:ACET) outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conference in New York, with President and CEO Chen... 
Via MarketBeat
News headline image
Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Announces Reverse Stock Split
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2 ↗
Adicet Bio reported strong Phase 1 lupus trial results with ADI-001, showing 100% response in nephritis patients and raising $80 million to fund Phase 2. 
Via Benzinga
News headline image
Tuesday's session: gap up and gap down stocks ↗
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.